News | September 07, 2008

Cardiolite Highlights Role in Molecular Breast Imaging Trial

September 7, 2008 - Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) by Lantheus Medical Imaging will be featured in a new study on molecular breast imaging being presented on Sunday, Sept. 7 2008, the company announced at the American Society of Clinical Oncology’s 2008 Breast Cancer Symposium in Washington, D.C.

Cardiolite, formerly marketed as Miraluma for the breast cancer imaging indication, is FDA approved for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Cardiolite is not indicated for breast cancer screening, or to confirm the presence or absence of a malignancy, or in place of a mammogram, and it is not an alternative to biopsy. This imaging test is used to assist in the evaluation of breast lesions in some women who have had an abnormal mammogram, or who have a palpable breast mass. In this test, a woman receives an injection of a small amount of a short-lived radioactive substance called Cardiolite, which is taken up by cancer cells, and a gamma camera is used to obtain images of the breasts.

“This promising new study on molecular breast imaging provides encouraging data for millions of women and families who are impacted by breast cancer and sheds light on potential new diagnostic approaches for finding tumors in women who have dense breast tissue, which can confound mammograms,” stated Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “We are proud to supply the imaging agent for this important clinical effort. Breast cancer is a devastating disease and we recognize how important and valuable early detection is for women.”

For more information: www.lantheus.com

Related Content

The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...